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Abstract
Plasmodium vivax can cause severe malaria, however its pathogenesis is poorly understood. In contrast to P. falciparum,
circulating vivax parasitemia is low, with minimal apparent sequestration in endothelium-lined microvasculature, and
pathogenesis thought unrelated to parasite biomass. However, the relationships between vivax disease-severity and total
parasite biomass, endothelial autocrine activation and microvascular dysfunction are unknown. We measured circulating
parasitemia and markers of total parasite biomass (plasma parasite lactate dehydrogenase [pLDH] and PvLDH) in adults with
severe (n = 9) and non-severe (n = 53) vivax malaria, and examined relationships with disease-severity, endothelial activation,
and microvascular function. Healthy controls and adults with non-severe and severe falciparum malaria were enrolled for
comparison. Median peripheral parasitemia, PvLDH and pLDH were 2.4-fold, 3.7-fold and 6.9-fold higher in severe compared
to non-severe vivax malaria (p = 0.02, p = 0.02 and p= 0.015, respectively), suggesting that, as in falciparum malaria,
peripheral P. vivax parasitemia underestimates total parasite biomass, particularly in severe disease. P. vivax schizonts were
under-represented in peripheral blood. Severe vivax malaria was associated with increased angiopoietin-2 and impaired
microvascular reactivity. Peripheral vivax parasitemia correlated with endothelial activation (angiopoietin-2, von-Willebrand-
Factor [VWF], E-selectin), whereas markers of total vivax biomass correlated only with systemic inflammation (IL-6, IL-10).
Activity of the VWF-cleaving-protease, ADAMTS13, was deficient in proportion to endothelial activation, IL-6,
thrombocytopenia and vivax disease-severity, and associated with impaired microvascular reactivity in severe disease.
Impaired microvascular reactivity correlated with lactate in severe vivax malaria. Findings suggest that tissue accumulation
of P. vivax may occur, with the hidden biomass greatest in severe disease and capable of mediating systemic inflammatory
pathology. The lack of association between total parasite biomass and endothelial activation is consistent with
accumulation in parts of the circulation devoid of endothelium. Endothelial activation, associated with circulating parasites,
and systemic inflammation may contribute to pathology in vivax malaria, with microvascular dysfunction likely contributing
to impaired tissue perfusion.
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Introduction
While P. falciparum accounts for a majority of severe and
fatal malaria cases worldwide, P. vivax is a major cause of
morbidity outside of Africa, causing an estimated 70–390
million malaria cases per year [1]. Although previously
considered benign, P. vivax is now recognized as capable of
causing severe and fatal disease [2,3,4,5,6,7,8,9,10]. Despite
this, little is known about the pathogenesis of severe disease in
vivax malaria.
In falciparum malaria, severe and fatal disease is characterised
by cytoadherence of parasitized red blood cells (RBCs) to activated
and dysfunctional endothelium, leading to parasite sequestration
with microvascular obstruction [11,12,13]. As a result of
sequestration the mature schizont stages of P. falciparum are
rarely seen in peripheral blood [14]. Total parasite biomass is
underestimated by circulating parasitemia quantitated by micros-
copy of peripheral blood, and is more accurately quantitated by
plasma P. falciparum histidine rich protein-2 (HRP2). Pathogen-
esis and disease severity in falciparum malaria are both biomass-
related: in contrast to peripheral parasitemia [15,16,17], plasma
HRP2 is strongly and independently correlated with disease
severity and mortality among both children [17,18,19,20] and
adults [21,22].
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Cytoadherence of infected RBCs to endothelial cells is 10-fold
less in P. vivax infection than in falciparum malaria [23], and
autopsy evidence for sequestration within the endothelium-lined
microvasculature of vital-organs in vivax malaria is minimal
[2,4,24]. This, together with the lower parasitemias resulting from
preferential invasion of reticulocytes, is thought to account for the
lower lethality of P. vivax [2]. The paucity of apparent endothelial
microvascular sequestration in vivax malaria has led to the
assumption that peripheral parasitemia reflects total parasite
biomass. However, this assumption has been questioned
[3,25,26], with more adhesive schizont-stages of P. vivax known
to be under-represented in peripheral blood [26,27]. Accumula-
tion of P. vivax-infected RBCs in the spleen or bone marrow has
been hypothesised [3,25,26] but not yet systematically investigat-
ed. In contrast to falciparum malaria, no study has evaluated the
relationships between total parasite biomass, disease severity and
systemic inflammation in vivax malaria. We propose that in vivax
malaria, parasite lactate dehydrogenase (pLDH) and P. vivax-
pLDH (PvLDH), produced by viable or recently killed parasites,
may be used to estimate total parasite biomass. While plasma
pLDH has been shown to demonstrate only moderate correlation
with peripheral parasitemia in vivax malaria [28], a pLDH
antigen capture enzyme-linked immunosorbent assay demonstrat-
ed a direct relationship between parasite production of pLDH and
total P. vivax parasite concentration ex vivo, including all parasite
stages, suggesting that pLDH reflects total P. vivax parasite
biomass [29]. As with HRP2 in falciparum malaria [30], pLDH is
produced to a greater extent by P. vivax schizonts and
trophozoites than by ring-form parasites [31], and given the
under-representation of mature P. vivax stages in peripheral blood
[26,27], pLDH may be a better marker of total parasite biomass
and a better prognostic indicator than peripheral parasitemia.
In falciparum malaria, clinical severity and mortality are also
independently associated with impaired microvascular function
[13] and with increased angiopoietin-2 (Ang-2) [32], a key product
of endothelial Weibel-Palade Bodies (WPB) and an autocrine
mediator of endothelial activation [33]. Despite the apparent
paucity of endothelial microvascular sequestration in vital organs,
P. vivax has been associated with greater endothelial activation
than P. falciparum, with Ang-2 concentrations higher in non-
severe vivax compared to non-severe falciparum malaria [34].
However the relationships between clinical severity, microvascular
dysfunction and endothelial WPB exocytosis have not been
assessed in vivax malaria.
We tested the hypotheses that in vivax malaria, peripheral
parasitemia would underestimate total parasite biomass, and that
markers of total parasite biomass would be related to systemic
inflammation and clinical severity. We also determined the
relationship between vivax disease severity and endothelial
activation and microvascular function, with patients with non-
severe and severe falciparum malaria included for comparison. We
found that total vivax biomass was underestimated by peripheral
parasitemia, and was associated with both systemic inflammation
and disease severity in vivax malaria. Severe vivax malaria was
associated with increased endothelial activation and WPB
exocytosis and with impaired microvascular function, comparable
to that seen in severe falciparum malaria.
Results
Patients
A total of 192 malaria patients and 74 healthy controls were
enrolled. Malaria patients included 62 with vivax malaria (53 non-
severe, 9 severe) and 130 with falciparum malaria (109 non-severe,
21 severe). The clinical and epidemiological features of 43 patients
with vivax malaria (including 7 with severe disease) and 122
patients with falciparum malaria (including 13 with severe disease)
have been previously reported [35]. Baseline characteristics are
shown in Table 1. Among the 9 patients with severe vivax malaria,
severity criteria included hypotension (n = 6), respiratory distress
(n = 1), jaundice (n = 2), metabolic acidosis (n = 1), abnormal
bleeding (n = 1) and multiple convulsions (n = 1). Three patients
had 2 severity criteria and 6 had one. Pre-antibiotic blood cultures
were negative in 4 patients, positive for Streptococcus pneumoniae
in one [35], and not done in 4. No deaths occurred from either
species.
Peripheral parasitemia, schizontemia, markers of total
parasite biomass and disease severity
In patients with vivax malaria, the median peripheral parasit-
emia was 2.4-fold higher in severe compared to non-severe disease
(10,243 parasites/mL vs. 4,209 parasites/mL; P= 0.021), while the
median PvLDH was 3.7-fold higher (96.6 ng/ml vs. 26.2 ng/ml;
P= 0.021) and pLDH 6.9-fold higher (308 ng/ml vs. 44.6 ng/ml;
P= 0.015) (Table 2 and Fig. 1). After removing the patient with
severe vivax malaria and concurrent bacteremia from the analysis,
the median peripheral parasitemia was 1.8-fold higher in severe
compared to non-severe disease (7,865 parasites/mL vs. 4,209
parasites/mL; P= 0.047), while the median PvLDH was 4.8-fold
higher (125 ng/ml vs. 26.2 ng/ml; P= 0.002) and pLDH 7.3-fold
higher (326 ng/ml vs. 44.6 ng/ml; P= 0.002). In falciparum
malaria, median peripheral parasitemia and plasma HRP2 were
4.2-fold and 7.4-fold higher, respectively, in severe compared to
non-severe disease (Table 2).
To estimate whether the ‘‘hidden parasite biomass’’ was larger
in severe compared to non-severe malaria, we calculated the ratio
of plasma pLDH and plasma PvLDH concentration to peripheral
parasite density in vivax malaria, and the ratio of plasma HRP2
Author Summary
How vivax parasites cause severe malaria is not known. In
contrast to falciparum parasites, the number of vivax
parasites circulating in peripheral blood is low, and there is
thought to be little sequestration of parasitized red cells
within endothelium-lined small blood vessels in vital
organs. Total parasite burden (circulating plus hidden)
and activation and dysfunction of the endothelial cells
lining blood vessels all contribute to severe disease in
falciparum malaria, but have not been evaluated in severe
vivax malaria. We measured parasite lactate dehydroge-
nase (pLDH) and P. vivax-pLDH (PvLDH) as proxies of total
parasite biomass and found that, as in falciparum malaria,
the total biomass of vivax parasites is underestimated by
counting parasites circulating in peripheral blood, sug-
gesting a hidden burden of vivax parasites. Markers of
total vivax biomass were strongly associated with illness-
severity and inflammatory cytokines, suggesting that this
hidden burden is capable of contributing to generalised
inflammation and hence severe disease. Number of
peripheral vivax parasites, but not total biomass, correlated
with activation of endothelial cells, suggesting that the
hidden vivax-infected red cells may accumulate in parts of
organs without endothelium, such as the slow-circulation
of the spleen or non-blood-vessel parts of the bone
marrow. Severe vivax malaria was associated with in-
creased endothelial activation and impaired microvascular
function, suggesting that these processes also contribute
to impaired blood flow and disease.
Parasite Biomass and Severe Vivax Malaria
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Fig. 1. Parasitemia (A) and total parasite biomass [pLDH (B), PvLDH (C), and HRP2 (D)] among patients with severe and non-severe
vivax and falciparum malaria.
doi:10.1371/journal.ppat.1004558.g001
Parasite Biomass and Severe Vivax Malaria
PLOS Pathogens | www.plospathogens.org 4 January 2015 | Volume 11 | Issue 1 | e1004558
concentration to peripheral parasite density in falciparum malaria.
Among patients with vivax malaria the ratios of PvLDH and
pLDH to parasite density (log) were 3.7-fold and 5.7-fold higher,
respectively, in severe compared to non-severe disease. The
corresponding fold-increase in the ratio of plasma HRP2 to
parasite count (log) in patients with severe compared to non-severe
falciparum malaria was 5.4.
Among patients with vivax malaria pLDH and PvLDH were
strongly correlated (r=0.90, P,0.0001). However there was only
a modest correlation between PvLDH and parasitemia (r=0.27,
P = 0.033), and between pLDH and parasitemia (r=0.28,
P = 0.028), comparable to the correlation between parasitemia
and plasma HRP2 among patients with falciparum malaria (r
=0.41, P,0.0001) (Fig. 2).
Among patients with vivax malaria who had detectable pLDH
and PvLDH levels on enrolment and in whom longitudinal
measurements could be performed (until day 3 or until undetect-
able), levels were undetectable by day 3 in 16/25 (64%) and 22/31
(71%) patients respectively.
In ex vivo assay conditions, P. vivax parasites exist as mature
schizonts for an estimated 5% of their 48-hour life-cycle [36].
Despite this, only 14/59 (24%) patients with vivax malaria had any
circulating schizonts detectable on peripheral blood film, including
2/9 (22%) with severe and 12/50 (24%) with non-severe disease.
Of those with schizonts detectable, schizonts comprised ,5% of
circulating parasites in 11/14 (78%) patients, including one with
severe and 10 with non-severe disease. There was a wide variation
in the proportion of peripheral P. vivax parasites at ring (median
33%, range 0–100%, IQR 9–77%) and trophozoite stage (median
67%, range 0–100%, IQR 20–91%). Among patients with severe
and non-severe vivax malaria, there were no differences between
the median percentage of rings or trophozoites in peripheral
blood.
Markers of endothelial activation and thrombosis,
cytokines, and clinical disease
Median concentrations of Ang-2 and von Willebrand Factor
(vWF), the two major products of endothelial WPB release, were
both increased in patients with severe and non-severe vivax
malaria compared to controls (P,0.01 for all comparisons), with
Ang-2 nearly twice as high in severe compared to non-severe
disease (P,0.0001) (Table 3). The median concentrations of the
endothelial adhesion receptors E-selectin and ICAM1 were also
increased in severe and non-severe vivax malaria compared to
controls (P,0.001 for all comparisons). In patients with vivax
malaria there was no association between age and any of the
endothelial activation markers measured. Median concentrations
of Ang-2, E-selectin and ICAM1 were at least as high in severe
and non-severe vivax malaria as they were in severe and non-
severe falciparum malaria (Table 3).
The median concentrations of the vWF-cleaving protease,
ADAMTS13, and its activity, were lower among patients with
severe and non-severe vivax malaria compared to controls (P,
0.001 for all comparisons), with median ADAMTS13 activity
also lower in severe compared to non-severe vivax malaria
(P = 0.027).
Median concentrations of IL-6 and IL-10 were higher in severe
and non-severe vivax malaria compared to controls (Table 3).
Parasitemia, markers of total parasite biomass, and
biomarkers of severity in vivax and falciparum malaria
In patients with vivax malaria, peripheral parasitemia correlated
with the endothelial WPB products, VWF (r =0.53, P,0.0001)
and Ang-2 (r=0.36, P= 0.004), as well as the endothelial
adhesion receptor E-selectin (r=0.33, P = 0.009), and was
inversely correlated with activity of the VWF-cleaving protease
ADAMTS13 (r=20.31, P= 0.055) (Table 4). Importantly, and in
contrast to peripheral parasitemia, no correlation was seen
between either of the total parasite biomass markers PvLDH or
pLDH, and the endothelial products VWF, Ang-2, or E-selectin
(Table 4).
While not associated with markers of endothelial activation,
PvLDH was correlated with the systemic inflammatory markers
IL-6 (r=0.27, P = 0.045) and IL-10 (r=0.28, P = 0.035), and, in
contrast to peripheral parasitemia, was inversely correlated with
baseline platelet count (r=20.26, P= 0.045) and with platelet
nadir (r=20.27, P= 0.035).
Among patients with falciparum malaria, biomarkers of
systemic inflammation correlated with both peripheral parasitemia
and the total parasite biomass marker, plasma HRP2 (Table 4). In
addition, and in contrast to vivax malaria, endothelial activation
correlated not only with peripheral parasitemia but also with total
parasite biomass (Table 4). Baseline platelet count and platelet
nadir also correlated with both peripheral parasitemia and HRP2
(Table 4).
Table 2. Parasite count and parasite biomass among patients with P. vivax and P. falciparum malaria.
P. vivax P. falciparum
Non-severe
(n=53)
Severe
(n=9)
P value (sev
vs. ns Pv)
Non-severe
(n =109)
Severe
(n=21)
P value (sev
vs. ns Pf)
Parasite count
(parasites/mL)
4,209
(1700–10,165)
10,243
(4387–19,520)
0.021 10,500
(4014–32,267)
44,332 (9079–273,
909)
0.002
PvLDH (ng/ml) 26.2 (10.7–57.3) 96.6 (85.6–154) 0.012
PvLDH/Log parasitemia 3.06 (1.33–7.73) 10.42 (9.27–18.60) 0.027
pLDH (ng/ml) 44.6 (7.8–142) 308 (258–619) 0.015 50.23 (22.9–121) 86.79 (39.3–452) 0.016
pLDH/Log parasitemia 6.46 (1.60–20.1) 36.7 (27.9–58.3) 0.021 5.54 (2.33–13.13) 7.58 (3.51–65.65) 0.058
HRP2 (ng/ml) 72.8 (32.8–260) 541 (125–1590) ,0.0001
HRP2/Log parasitemia 9.04 (3.38–23.55) 49.0 (13.8–196) 0.0002
Note: Values are median (inter-quartile range).
Ratios are calculated as ngs/1000 peripheral parasites, with the denominator log-transformed to a normal distribution.
doi:10.1371/journal.ppat.1004558.t002
Parasite Biomass and Severe Vivax Malaria
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Ang-2, ADAMTS13, and biomarkers of severity among
patients with vivax malaria
In patients with vivax malaria, Ang-2, in addition to correlating
with parasitemia, correlated with the adhesion receptors E-selectin
(r=0.40, P= 0.001) and ICAM-1 (r=0.54, P,0.0001), and
inversely with
ADAMTS13 antigen (r=20.41, P= 0.010) and activity levels
(r=20.60, P= 0.0001), with all associations remaining significant
after adjusting for parasitemia.
ADAMTS13 antigen and activity levels correlated with platelet
count (r=0.36, P= 0.025; and r=0.56, P= 0.0003, respectively),
with this association remaining significant after adjusting for
parasitemia. IL-6, elevated in vivax malaria, is known to be a
major inhibitor of ADAMTS13 activity [37]. In vivax malaria, IL-
6 was inversely correlated with ADAMTS13 activity (r=20.40,
P= 0.013) and platelet nadir (r =20.44, p = 0.0009). No associ-
ation occurred between lactate and ADMATS13 antigen and
activity levels, or between lactate and Ang-2.
Microvascular function
Microvascular reactivity (assessed using Near Infrared Reso-
nance Spectroscopy [13]) was decreased in patients with severe
vivax malaria (median 5.44 units/sec) compared to those with
non-severe vivax malaria (median 6.98 units/sec; P= 0.006) and to
controls (median 6.34, P= 0.027) (Table 3 and Fig. 3). Microvas-
cular reactivity was also impaired among patients with severe
falciparum malaria (median 4.88 units/sec) compared to those
with non-severe falciparum malaria (6.31 units/sec; P= 0.024) and
controls (P = 0.016), with the degree of impairment similar
between severe vivax and severe falciparum malaria. In both
species, there was no significant difference between controls and
patients with non-severe malaria.
Among patients with vivax malaria, microvascular reactivity
was inversely associated with the perfusion marker, lactate, in
severe (r=20.74, P = 0.04), but not non-severe disease (r=0.09,
P= 0.62). In severe disease ADAMTS13 antigen and activity levels
correlated with microvascular reactivity (r=0.64 and P= 0.09, for
both associations), although no association occurred in non-severe
disease (r=0.07, P= 0.78; and r=20.02, P= 0.95; respectively).
No association was found between microvascular reactivity and
other variables in vivax malaria, including parasitemia or biomass
markers.
In patients with falciparum malaria, microvascular reactivity
was inversely correlated with parasitemia (r=20.22, P = 0.035),
and positively correlated with platelet count (r=0.017, P = 0.017).
Among patients with severe and non-severe falciparum malaria,
no association occurred between microvascular reactivity and
lactate, or between microvascular reactivity and ADAMTS13
antigen or activity. In both species there was no association
between microvascular reactivity and age.
Among patients with vivax malaria, 6 patients with severe and
16 with non-severe disease had NIRS repeated on day 3, with no
change from baseline noted in either group (median microvascular
reactivity on day 3 = 5.59 units/sec and 7.39 units/sec
respectively). In severe falciparum, microvascular reactivity
improved from 4.88 units/sec at enrolment to 6.51 units/sec on
day 3 (P= 0.039), although no difference was noted among 37
patients with non-severe falciparum malaria (median microvascu-
lar reactivity on day 3= 6.56 units/sec, P= 0.437)
Discussion
Peripheral parasitemia underestimates measures of total para-
site biomass in vivax malaria and circulating schizonts are
Fig. 2. Parasitemia and markers of total parasite biomass
among patients with vivax and falciparum malaria. (A)
Correlation between parasitemia and PvLDH among patients with
vivax malaria, Spearman’s r= 0.27, P = 0.033, (B) Correlation between
parasitemia and pLDH among patients with vivax malaria, Spearman’s
r= 0.27, P = 0.028, and (C) correlation between parasitemia and
HRP2 among patients with falciparum malaria, Spearman’s r= 0.41,
P =,0.0001.
doi:10.1371/journal.ppat.1004558.g002
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under-represented in peripheral blood, suggesting tissue accumu-
lation of a hidden biomass of P. vivax-infected RBCs. The
proportions of total parasite biomass detectable in peripheral
blood in uncomplicated and severe disease were of comparable
magnitude in vivax and in falciparum malaria. The association
between P. vivax peripheral parasitemia and total parasite
biomass is modest, with total parasite biomass more strongly
associated with disease severity compared to peripheral parasit-
emia. The smaller proportion of total P. vivax biomass detectable
in peripheral blood in severe compared to non-severe disease
suggests that hidden biomass is greater in severe vivax malaria and
contributes to pathogenesis of disease. The association of total
vivax parasite biomass with systemic inflammation suggests that
the hidden biomass is capable of mediating systemic inflammatory
pathology. In contrast to peripheral P. vivax parasitemia, total
parasite biomass did not correlate with endothelial activation, and
we therefore speculate that accumulation of P. vivax-infected
RBCs may occur in parts of the circulation devoid of endothelium.
In falciparum malaria, peripheral parasitemia underestimates
the total parasite biomass due to sequestration of parasitized RBCs
within endothelium-lined microvasculature. While P. vivax is not
thought to sequester in the endothelium-lined microvasculature to
the same degree as P. falciparum, limited histopathological reports
show intact P. vivax-infected RBCs in the bone marrow
[38,39,40,41,42,43] and spleen [44,45], organs containing circu-
latory compartments that are not endothelium-lined. The spleen is
a lymphoid organ whose primary role is to clear abnormal
erythrocytes from the circulation, and hence plays a fundamental
role in removing parasitized RBCs, especially in falciparum
malaria where RBC deformability is markedly decreased. In
falciparum malaria, endothelial cytoadherence of infected RBCs
enable the parasite to sequester in non-splenic microvasculature
and avoid passage through the spleen. In contrast, P. vivax-
infected RBCs cytoadhere with less avidity to endothelial cells
[23], and demonstrate increased deformability [46,47], allowing
circulation through the spleen. While 80-90% of splenic blood flow
occurs through endothelial-lined sinuses, the remainder circulates
through a parallel slow, open circulation in the splenic cords,
devoid of endothelial cells [48]. In a recent report involving a
splenectomised patient with vivax malaria, large numbers of intact
non-phagocytosed P. vivax-infected reticulocytes were found in
the splenic cords [44]. Accumulation of P. vivax-infected
reticulocytes in the slow open microcirculation of the spleen,
possibly through reticulocyte adherence to non-endothelial resi-
dent cells [49,50,51,52], has been proposed as a mechanism by
which P. vivax may avoid macrophage clearance [53] yet readily
invade new reticulocytes.
The findings of our study suggest that tissue accumulation of P.
vivax does occur and is greatest in severe vivax malaria, and we
speculate it may occur in a location devoid of endothelium, such as
the slow circulation of the spleen. We found no correlation
between the P. vivax biomarkers of total biomass, pLDH and
PvLDH, and either of the two products of endothelial WPB
release, Ang-2 or VWF, or the endothelial adhesion receptor E-
selectin. In contrast, peripheral parasitemia correlated with
endothelial activation (Ang-2, VWF and E-selectin) in both vivax
and falciparum malaria, and with total biomass (HRP2) in
falciparum malaria. These findings suggest that endothelial cells
may be activated by P. vivax-infected RBCs circulating through
the peripheral microvasculature, but not by the hidden P. vivax
biomass. Accumulation of P. vivax in the endothelium-free open
circulation of the spleen may account for these findings. The
finding that P. vivax peripheral parasitemia and markers of total
parasite biomass both correlated with the leukocyte-derived
cytokines may reflect the ability of circulating and tissue-
accumulated P. vivax to stimulate leukocytes in both peripheral
blood and leukocyte-containing organs such as the spleen or bone
marrow, and thereby mediating organ dysfunction secondary to
systemic inflammation.
Although underestimating total biomass, peripheral parasitemia
was still higher in severe compared to non-severe malaria in both
P. vivax and P. falciparum, and endothelial activation was higher
in patients with severe disease. Ang-2 concentrations were twice as
high in severe compared to non-severe vivax malaria, and
comparable to levels seen in severe falciparum malaria. Ang-2,
which causes autocrine endothelial activation, has previously been
shown to be markedly elevated in severe falciparum malaria and a
consistent predictor of death in both adults [32,54,55] and
children [56,57]. In severe falciparum malaria Ang-2 correlates
with impaired endothelial function, lactate, plasma HRP2, ICAM-
1, and E-selectin [32]. In our study, Ang-2 was also associated with
ICAM-1 and E-selectin among patients with vivax malaria,
consistent with the role of Ang-2 in activating endothelium in
vivax as well as falciparum malaria [32]. Our findings of increased
Fig. 3. Microvascular function (skeletal muscle reoxygenation)
among patients with vivax (A) and falciparum (B) malaria.
doi:10.1371/journal.ppat.1004558.g003
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endothelial activation in severe vivax malaria are consistent with a
recent study reporting higher concentrations of ICAM-1 and
VCAM-1 in severe compared to uncomplicated vivax malaria
[58].
Microvascular function was significantly impaired in severe
vivax malaria, comparable to the impairment seen in severe
falciparum malaria. As previously shown in severe falciparum
malaria [13], the impairment of microvascular reactivity in severe
vivax malaria was strongly associated with blood lactate,
suggesting that impaired tissue perfusion is contributing to organ
dysfunction in severe vivax malaria.
Plasma ADAMTS13 activity was decreased in vivax malaria,
with deficiency associated with both severe disease and with
impaired microvascular function. ADAMTS13 is a protease that
cleaves ultra-large and prothrombogenic VWF multimers (UL-
VWF), and deficiency leads to accumulation of UL-VWF with
resultant increase in platelet aggregation and adhesion, and
microvascular thrombosis. Accumulation of UL-VWF resulting
from ADAMTS13 deficiency is characteristic of the microangio-
pathic disease thrombotic thrombocytopenic purpura (TTP), and
has been reported in patients with both falciparum and vivax
malaria [59]. While renal failure was not a feature of patients with
severe vivax malaria in our study, thrombotic microangiopathy
has been reported in severe vivax disease elsewhere [60,61]. In our
study, lower ADAMTS13 antigen and activity levels were
associated with lower platelet counts, and with increased
concentrations of IL-6, a known specific inhibitor of ADAMTS13
activity [37]. We speculate that biomass-related IL-6 may
contribute to impaired ADAMTS13 activity and accumulation
of UL-VWF multimers, and may thereby contribute to microvas-
cular dysfunction, thrombocytopenia and disease severity in vivax
malaria. Further studies however are required to confirm the
mechanisms underlying ADAMTS13 deficiency in vivax malaria,
and to investigate the role of thrombotic microangiopathy.
Our study had several limitations. Firstly, pLDH and PvLDH
have not been previously validated as biomass markers in vivax
malaria. Other factors may contribute to the plasma concentra-
tions of these markers, such as host metabolic clearance rate,
distribution within the host and diffusion rates from host tissue,
and natural variation in parasite expression. Release of pLDH
solely at the time of schizont rupture may provide a possible
alternative explanation for the association between concentrations
of pLDH/PvLDH, systemic inflammation and disease severity,
with schizogony also associated with an inflammatory response
[62]. However, we have demonstrated that ex-vivo concentrations
of PvLDH increase progressively during short term culture of P.
vivax, indicating that PvLDH is secreted throughout the parasite
life-cycle and supporting the use of pLDHand PvLDH as
surrogate markers of parasite biomass. Host inflammatory
response may contribute in part to the marked under-represen-
tation of P. vivax schizonts in peripheral blood, however this
would apply similarly to hosts infected with other Plasmodium
species with under-representation of schizonts in peripheral blood,
such as P. falciparum or P. coatneyi, whose schizonts have been
clearly shown to sequester in tissues [63].
The small number of patients with severe vivax malaria (n = 9)
limited our ability to evaluate the association between disease
severity and other variables, and to assess for associations of
parasite biomass and/or parasitemia that may have occurred only
among patients with severe disease. In addition, with multiple
comparisons we are unable to exclude the possibility that
associations may have occurred by chance. However, the
magnitude and direction of the associations with disease severity
and with different measures of biomass are consistent, plausible,
and are comparable to those in patients with falciparum malaria.
Pre-antibiotic blood cultures were not performed in all our
patients, and hence it is possible that as in falciparum malaria
[64,65], concurrent bacteremia may have contributed to the
clinical features of some patients with severe vivax malaria.
However, the much higher biomass in patients with severe
compared to non-severe vivax cannot have been accounted for by
concurrent bacteremia, or the parasitemia- or biomass-related
associations we found. Finally, while we demonstrated increased
endothelial activation among patients with vivax malaria in
proportion to disease severity [34], the causes of WPB exocytosis
in vivax malaria were not evaluated and require further study.
In summary, peripheral parasitemia underestimates total
parasite biomass in vivax malaria, particularly in severe disease,
suggesting tissue accumulation of a hidden biomass of P. vivax-
infected RBCs. While histological studies are needed to confirm
this, we propose that a hidden P. vivax biomass is capable of
mediating systemic inflammation which may contribute to organ
dysfunction. The correlation of markers of total P. vivax biomass
with systemic inflammation but not with markers of endothelial
activation is consistent with the hypothesis that accumulation of P.
vivax-infected red cells may occur in parts of the circulation
devoid of endothelium, such as the open circulation of the spleen
or extravascular bone marrow. In contrast only peripheral
parasitemia was associated with endothelial activation and the
Weibel Palade Body products Ang-2 and VWF. The association
between clinical severity and endothelial activation, ADAMTS13
deficiency, thrombocytopenia, and impaired microvascular func-
tion suggests that thrombotic microangiopathy, systemic inflam-
mation and microvascular dysfunction may contribute to patho-
genesis of disease in vivax malaria.
Methods
Study site and patients
This study was conducted in Sabah, Malaysia, a region
currently in the pre-elimination phase of malaria control and
where P. vivax endemicity is low [66,67]. Patients were enrolled as
part of a prospective clinical and epidemiological study of all
malaria patients admitted to Queen Elizabeth Hospital, an adult
tertiary referral hospital [35]. Consecutive patients with PCR-
confirmed vivax or falciparum monoinfection were enrolled from
September 2010 – October 2012 (with non-severe falciparum
malaria patients included up until October 2011) if they were
non-pregnant, $12 years old, had no major comorbidities or
concurrent illness, were within 18 hours of commencing antima-
larial treatment, had haemoglobin .7.0 g/dL, and had not been
previously enrolled in the study. Clinical details of patients
enrolled from September 2010 – October 2011, in addition to
details regarding excluded patients, have been previously
reported [35]. Severe malaria was defined as the presence of
$1 of: unrousable coma (Glasgow Coma Scale score ,11);
multiple ( .2) convulsions; respiratory distress (respiratory rate
.30 breaths per minute and oxygen saturation ,94%);
hypotension (systolic blood pressure #80 mm Hg); jaundice
(bilirubin .43 mmol/L plus parasitemia .20 000/mL [P. vivax]
or .100,000 [P. falciparum] and/or creatinine .132 mmol/L);
significant abnormal bleeding; hypoglycaemia (blood glucose
,2.2 mmol/L); metabolic acidosis (bicarbonate ,15 mmol/L or
lactate .4 mmol/L); acute kidney injury (AKI; creatinine
.265 mmol/L); hyperparasitemia (P. falciparum parasitemia
.10%). Healthy controls were visitors or relatives of malaria
patients, with no history of fever in the past 48 hours and with
blood film negative for malaria parasites.
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Standardized history and physical examination were document-
ed. Haematology, biochemistry, acid-base parameters, and lactate
(by bedside blood analysis; iSTAT system) were obtained on
admission. Parasite counts were determined by microscopy, and
parasite species were identified by PCR [68,69]. Patients were
treated according to hospital guidelines, as previously described
[35].
Endothelial activation, WPB release, ADAMTS13 and
cytokines
Venous blood collection in lithium heparin was centrifuged
within 30 minutes of collection and plasma was stored at 270uC.
Plasma concentrations of the endothelial activation markers
ICAM-1, E-selectin, and Ang-2 were measured using ELISA
(R&D Systems), and IL-6 and IL-10 were measured by flow
cytometry (BD Cytometric Bead Array). Antigen concentrations of
vWF and the vWF-cleaving enzyme, ADAMTS13, were measured
in platelet poor plasma using ELISA (America Diagnostica), and
ADAMTS 13 activity by fluorescence resonance energy transfer
(FRET), as previously described [70].
Parasitemia and markers of total parasite biomass
Peripheral blood parasitemia was quantitated per 200 white
blood cells by microscopy and expressed as parasites/mL based on
automated white cell count. Parasite stage distribution was
quantitated on microscopy of peripheral blood. Plasma HRP2
(for P. falciparum) [32], genus-specific pLDH (for P. falciparum
and P. vivax) and PvLDH (for P. vivax) were measured by ELISA
[28] as proxies for total parasite biomass. Ratios of plasma pLDH
and PvLDH to peripheral parasite density were expressed as ngs/
1000 peripheral parasites, with the denominator log-transformed.
PvLDH production in vitro
To confirm evidence of PvLDH secretion across the parasite
life-cycle, four cryopreserved P. vivax isolates with a high
proportion of ring-stages were thawed and cultured ex-vivo as
previously described [71], over 48–54 hours. Starting parasitemias
were 3623/mL (98% rings), 10,605/mL (98% rings), 19,342/mL
(65% rings), and 24,680/mL (98% rings). Thick and thin films were
prepared at serial time points for stage differential and culture
supernatant sampled for concentration of PvLDH. A progressive
increase in concentration of PvLDH in culture supernatant across
the parasite life-cycle was demonstrated (Text S1), indicating
secretion of PvLDH by all parasite stages. In vitro parasitemia
remained stable throughout the culture duration.
Microvascular function
Microvascular function was assessed using Near Infrared
Spectroscopy (InSpectra 650, Hutchinson Technology, Hutch-
inson, MN) which uses a probe applied to the thenar eminence to
noninvasively measure microcirculatory oxygenation (tissue oxy-
gen saturation; StO2) before and after an ischaemic stress, as
previously described [13]. To induce an ischaemic stress, a
vascular cuff was inflated to 200 mm Hg for 5 minutes and then
rapidly deflated. Microvascular function was defined as the
gradient of the StO2 recovery slope from release of the vascular
cuff until StO2 had reached 85% of the baseline value.
Statistical methods
Statistical analysis was performed with STATA software
(version 10.1; Statacorp, College Station, TX, USA). For
continuous variables intergroup differences were initially com-
pared using analysis of variance or Kruskal-Wallis tests depending
on distribution. Student’s T-test or Mann-Whitney tests were used
for post-hoc pair-wise comparisons. Categorical variables were
compared using x2 or Fisher’s exact test. Associations between
continuous variables were assessed using Spearman’s (r) or
Peason’s (r) correlation coefficients, depending on distribution.
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